Compare Citius Pharmaceuticals Inc (CTXR) vs Veritone Inc (VERI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Veritone Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Veritone Inc trades at $0.56 (market cap $59.46M). The key difference: Veritone Inc is far larger — about 4.4× Citius Pharmaceuticals Inc's market cap, and Citius Pharmaceuticals Inc is more actively traded (132,438 versus 15,523,164). Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Veritone Inc for 12 Days on average.
| CTXR | VERI | |
|---|---|---|
Market Cap | $13.62M | $59.46M |
Volume | 132,438 | 15,523,164 |
Sector | Health | Technology |
52-Week High | $1.82 | $8.39 |
52-Week Low | $0.48 | $0.59 |
Typical Hold Time | 17 Days | 12 Days |
Enterprise Value | $3.79M | $94.86M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.4994, down 1.73% with a bearish technical signal despite oscillators showing oversold conditions. The company reported $7.1M revenue for the first nine months of 2026 from LYMPHIR commercial sales, but continues to post significant losses with a -651.27% net income margin. Recent news highlights strong commercial momentum for LYMPHIR with 44 institutions ordering the treatment since launch.
The stock presents a high-risk opportunity with analyst consensus strongly bullish (83% buy ratings, $5 price target) but fundamental challenges persist. Key risks include ongoing cash burn and execution of commercial strategy, while potential upside depends on successful LYMPHIR adoption and path to profitability.
Veritone (VERI) trades at $0.5647, down 18.31% over 24 hours, reflecting significant bearish pressure. The stock shows mixed signals with a bearish technical outlook but bullish oscillators. Fundamentally, the company reported a net loss of $111.73M in 2025 with a negative net income margin of -117.54%, though revenue remains near $92M. Recent developments include a $15M equity offering and partnerships with ATP Media and ZeroEyes, indicating ongoing business development efforts amidst financial challenges.
The outlook for VERI is highly speculative, with a consensus analyst price target of $3.75 suggesting substantial upside potential from current levels. However, persistent losses, negative cash flow from operations, and ongoing securities litigation pose significant risks. Investment appeal hinges on the company's ability to achieve profitability and monetize its AI solutions, making it suitable only for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Veritone Inc
Veritone is a leading provider of enterprise AI software and solutions, centered on its proprietary AI operating system, aiWARE™. The platform orchestrates a vast ecosystem of machine learning models to transform unstructured data—such as audio, video, and text—into actionable intelligence. Serving the media, entertainment, and public sectors, Veritone is a critical infrastructure partner for organizations looking to monetize data archives and operationalize AI at scale.
Read more on VERI →
